

## Protein Domains Involved in both In Vivo and In Vitro Interactions between Human T-Cell Leukemia Virus Type I Tax and CREB

MIN-JEAN YIN, EYVIND J. PAULSSEN, JACOB-S. SEELER, AND RICHARD B. GAYNOR\*

*Division of Molecular Virology, Departments of Internal Medicine and Microbiology,  
University of Texas Southwestern Medical Center, Dallas, Texas 75235-8594*

Received 21 November 1994/Accepted 16 February 1995

**Gene expression from the human T-cell leukemia virus type I (HTLV-I) long terminal repeat (LTR) is mediated by three *cis*-acting regulatory elements known as 21-bp repeats and the transactivator protein Tax. The 21-bp repeats can be subdivided into three motifs known as A, B, and C, each of which is important for maximal gene expression in response to Tax. The B motif contains nucleotide sequences known as a cyclic AMP response element (CRE) or *tax*-response element which binds members of the ATF/CREB family of transcription factors. Though mutations of this element in the HTLV-I LTR eliminate *tax* activation, Tax will not activate most other promoters containing these CRE sites. In this study, we investigated the mechanism by which Tax activates gene expression in conjunction with members of the ATF/CREB family. We found that Tax enhanced the binding of one member of the ATF/CREB family, CREB 1, to each of the three HTLV-I LTR 21-bp repeats but not another member designated CRE-BP1 or CREB2. Tax enhanced the binding of CREB1 to nonpalindromic CRE binding sites such as those found in the HTLV-I LTR, but Tax did not enhance the binding of CREB1 to palindromic CRE binding sites such as found in the somatostatin promoter. This finding may help explain the failure of Tax to activate promoters containing consensus CRE sites. These studies were extended by use of the mammalian two-hybrid system. Tax was demonstrated to interact directly with CREB1 but not with other bZIP proteins, including CREB2 and Jun. Site-directed mutagenesis of both Tax and CREB1 demonstrated that the amino terminus of Tax and both the basic and the leucine zipper regions of CREB1 were required for direct interactions between these proteins both in vivo and in vitro. This interaction occurred in vivo and thus did not require the presence of the HTLV-I 21-bp repeats, as previously suggested. These results define the domains required for interaction between Tax and CREB that are likely critical for the activation of HTLV-I gene expression.**

Human T-cell leukemia virus type I (HTLV-I) is a human retrovirus which is the etiologic agent of adult T-cell leukemia/lymphoma (34, 55, 74) and a degenerative neurologic syndrome designated tropical spastic paraparesis (26, 52). The HTLV-I genome encodes a number of regulatory proteins, including Tax and Rex, which are involved in controlling viral gene expression and pathogenesis (11). The 40-kDa transactivator protein Tax is critical for modulating the level of HTLV-I gene expression (7, 15, 22, 66) and is also involved in the cellular transformation of human T lymphocytes (32, 70). In addition to regulating HTLV-I gene expression, Tax has also been demonstrated to activate gene expression from other viral and cellular genes, including those from the interleukin-2 (IL-2), IL-2 receptor  $\alpha$ , *c-fos*, and human immunodeficiency virus type 1 (HIV-1) promoters (18–20, 38, 43), and it also represses gene expression from the DNA polymerase- $\beta$  promoter (41). Thus, Tax is an important modulator of both viral and cellular gene expression.

The HTLV-I long terminal repeat (LTR) contains three relatively conserved elements, designated 21-bp repeats, which are necessary for transactivation by Tax (6, 23, 54, 61). The 21-bp repeats have been further subdivided into three motifs designated A, B, and C (24, 49). The B motif in each of the 21-bp repeats contains the sequence TGACG, which is designated as a cyclic AMP response element (CRE) or the *tax* response element. This element is capable of serving as the

binding site for members of the ATF/CREB family of transcription factors (2, 3, 68, 72, 75–77) in addition to other factors such as HEB1 and HEB2 (4, 49). Though the A and C motifs within the 21-bp repeat are important for *tax* activation, mutation of the B motif which eliminates *tax* activation appears to be key (24, 27, 49, 58, 69). In addition, the B motif can mediate activation of HTLV-I gene expression in response to increases in cyclic AMP, indicating that factors normally regulated by cyclic AMP such as CREB may bind to the 21-bp repeat (40, 56). However, *tax* activation of most other viral and cellular promoters is mediated by the binding sites of transcription factors other than ATF/CREB. For example, *tax* activation of the IL-2 receptor  $\alpha$  promoter (10, 38, 43) and the HIV-1 LTR (5, 60, 62, 66) is mediated by NF- $\kappa$ B sites. Tax activation of the *c-fos* (18, 19) or the parathyroid hormone-related protein gene (73) is modulated through upstream factor binding sites for proteins, including SRF and AP-2. Thus, it is likely that Tax may either directly or indirectly alter the activity of a variety of different transcription factors to increase the level of gene expression from *tax*-responsive genes.

The mechanism by which Tax activates HTLV-I gene expression has been the subject of intense investigation. Tax does not bind directly to DNA elements in the HTLV-I LTR or other promoters (3, 25, 27, 48). Instead, through the use of in vitro binding assays, Tax has been demonstrated to directly interact with cellular transcription factors which bind to the HTLV-I LTR, including members of the ATF/CREB family (53, 67, 72, 76, 77), HEB1 (4), and TFIID (8). Gel retardation analysis suggests that Tax stimulates the binding of CREB to the B motif within the 21-bp repeats (17, 72, 76), though it is not clear whether this association is stable during electro-

\* Corresponding author. Mailing address: Division of Molecular Virology, Department of Internal Medicine, U.T. Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-8594. Phone: (214) 648-7570. Fax: (214) 648-8862.

phoresis (2, 17, 72, 76, 77). It is also controversial whether Tax has specificity for one or more members of the CREB/ATF family (2, 17, 72, 76). In fact, one study suggests that Tax can stimulate the DNA binding properties of a variety of basic leucine zipper-binding (bZIP) proteins to their cognate binding sites (2, 17, 72). This latter result raises questions about how Tax could increase the binding of a variety of cellular transcription factors yet still have relatively specific targets for the activation of gene expression. The demonstration that Tax will not activate gene expression from a variety of different promoters containing CRE sites further points to marked specificity requirements for *tax* activation (24).

A number of members of the ATF/CREB family have been demonstrated to bind to the 21-bp repeat (75). These include TREB7, which is identical to CRE-BP1 and differs by two amino acids from ATF-2, and TREB 36, which is identical to ATF-1 and is highly homologous to CREB (29, 33, 37, 75). On the basis of the terminology of the Nomenclature Committee of the Human Genome Project, we will refer to CREB as CREB1 and CRE-BP1 as CREB2 (12, 71). In this study, we addressed the specificity of Tax interaction with members of the ATF/CREB family and other leucine zipper proteins by using both *in vitro* interaction studies and the mammalian two-hybrid system. Furthermore, we used mutagenesis to determine motifs in CREB1 and Tax necessary for their interaction both *in vivo* and *in vitro*. Finally, we explored the effects of Tax on CREB1 binding to both consensus and nonconsensus CRE sites. These studies suggest that specific interactions between Tax and CREB1 in the context of nonpalindromic CRE binding sites are critical for Tax activation of the HTLV-I LTR.

## MATERIALS AND METHODS

**Plasmid constructs.** All clones constructed after PCR were analyzed and confirmed by DNA sequence analysis. The full-length CREB1 cDNA (37), the  $\Delta$ N2 (4-274), and the  $\Delta$ C (267-341) CREB1 deletion constructs were cloned downstream of the glutathione *S*-transferase (GST) protein in pGEX-2T. A *Bam*HI-*Eco*RI full-length CREB1 cDNA fragment was cloned into the pGEX-2T vector. The amino-terminal truncation was created by PCR with an oligonucleotide primer (5'-GTTGCCATGGCATCTCCCCAGC-3') which created an in-frame *Nco*I site and a 3' oligonucleotide primer (5'-AATCCCC ATGGAATCTGATTGGCAGTAAAGG-3'), with CREB1 cDNA as a template. This PCR product was then cut with *Nco*I-*Xho*I and cloned into the pGEX-2T vector. The 5' PCR primer creating the carboxy-terminal truncation of CREB1 was made with the 5' oligonucleotide primer 5'-CAGAAAGTGAAGA TTCACAG-3' and the 3' primer 5'-TTCCCATGGATTCTTCAGCAGGCTGT GTAGG-3'. The PCR product was digested with *Kpn*I-*Sma*I and cloned into the pGEX-2T vector.

The wild-type Tax and amino-terminal Tax truncation  $\Delta$ N2 (2-136) were inserted in the *Nco*I restriction site of plasmid pQE60 (Qiagen). The amino-terminal truncation of Tax  $\Delta$ N2 was constructed by PCR with a 5' oligonucleotide primer, 5'-TCCAGCCATGGGACTCCGGCCCCAAAACCTG-3', which created an in-frame *Nco*I site, and with a 3' primer, 5'-GTCGGCAAATATCG CATGC-3'. Both the Tax cDNA and the Tax $\Delta$ N2 construct were digested with *Nco*I and cloned into *Nco*I-digested pQE60 vector. The two resulting plasmids, pQE60-Tax-E6K and pQE60-E6K Tax $\Delta$ N2, produced a fusion protein which included the Tax coding sequence, the influenza virus hemagglutinin epitope, a 6x histidine tag, and a substrate sequence (RRASV) for protein kinase A phosphorylation.

The 5x GAL-E1B-CAT reporter plasmid containing five GAL4 DNA binding sites and the E1B TATA box linked to the chloramphenicol acetyltransferase (CAT) gene have previously been described (57). The Tax-GAL eucaryotic expression vector was constructed by fusing an *Nco*I-cut Tax cDNA (58) fragment in frame with the GAL4 (1-147) coding sequences in the pDP18 expression vector, which contains a Rous sarcoma virus promoter and a simian virus 40 polyadenylation site. The Tax amino- and carboxy-terminal truncations Tax $\Delta$ N1 ( $\Delta$ 3-93), Tax $\Delta$ N2 (2-136), Tax $\Delta$ C1 ( $\Delta$ 337-353), Tax $\Delta$ C2 ( $\Delta$ 317-353), and Tax $\Delta$ C3 ( $\Delta$ 297-353) were constructed by PCR. The primers for PCR created in-frame *Nco*I sites on both the 5' and 3' ends. The PCR primers used for these constructs included the Tax $\Delta$ N1 ( $\Delta$ 3-93) 5' primer, 5'-CTTACCATTGCAATCATCATA CAACCCCAAC-3', and 3' primer, 5'-GTCGGCAAATATCGCATGC-3'; the Tax $\Delta$ C1 ( $\Delta$ 337-353) 5' primer, 5'-CCACAAATTGATAAGTACTTG, and 3' primer, 5'-GCCCCCATGGATATTTGGGCTCATG-3', the Tax $\Delta$ C2 ( $\Delta$ 317-

353) 5' primer, 5'-TAATACGACTCACTATAGG-3', and 3' primer, 5'-CGCT CCATGGATCCGGGGATGTTGGTGTATTC-3', and the Tax $\Delta$ C3 ( $\Delta$ 297-353) 5' primer, 5'-TAATACGACTCACTATAGG-3', and 3' primer, 5'-CGCTCC ATGGATCCGAGGCCGTGTGAGAGTAG-3'. The PCR products were digested with *Nco*I and cloned in frame upstream of the GAL4 (1-147) sequence in the pDP18 vector.

CREB1-VP16, CREB2-VP16, and Jun-VP16 fusions were constructed by insertion of these complete cDNA fragments in frame upstream of the VP16 (412-490) activation domain and a simian virus 40 nuclear localization signal in the pDP18 expression vector. CREB deletion constructs CREB $\Delta$ N1 ( $\Delta$ 4-136), CREB $\Delta$ N2 ( $\Delta$ 4-274), and CREB $\Delta$ C ( $\Delta$ 267-341) were constructed by PCR. The PCR primers used to construct amino- and carboxy-terminal truncations of CREB with *Nco*I sites at each end are the CREB $\Delta$ N1 ( $\Delta$ 4-136) 5' primer, 5'-CACTACCATGGAAAGTGAAGATTCACAGGAG-3', and 3' primer, 5'-AT TCCCATGGAAATCTGATTGTTGGCAGTAAAGG-3'; the CREB $\Delta$ N2 ( $\Delta$ 4-274) 5' primer, 5'-GTTGCCATGGCATCTCCCCAGC-3', and 3' primer, 5'-AATCCCCATGGAATCTGATTGTTGGCAGTAAAGG-3'; and the CREB $\Delta$ C ( $\Delta$ 267-341) 5' primer, 5'-CAGAAAGTGAAGAATTCACAG-3', and 3' primer, 5'-TTCCCATGGATTCTTCAGFAGGCTGTGTAGG-3'. The PCR products were digested with *Nco*I and then cloned in frame upstream of the VP16 (412-490) sequence in the pDP18 vector.

To construct point mutations of Tax and CREB1, single-stranded M13 DNAs were isolated and site-directed mutagenesis was performed with an oligonucleotide-directed *in vitro* mutagenesis system (Amersham). These mutant Tax and CREB cDNAs were subcloned either upstream of GAL4 (1-147) or upstream of VP16 (412-490), respectively, in the pDP18 vector and confirmed by sequencing. The oligonucleotide primers for the Tax mutants M1 (H-3 $\rightarrow$ S), M2 (G-137L $\rightarrow$ AS), and M47 (L-319L $\rightarrow$ RS) were 5'-CACCATGGCCTCCTCCAGGGTT TGGAC-3', designed to change His-3 to Ser; 5'-CTTTCCAGACCCCGCTAG CCGGCCAAAACCTG-3', designed to change Gly-137 and Leu-138 to Ala and Ser, respectively; and 5'-CCAACATCCCCATTCTAGATCTTTTAACG AAAAAGAGG-3', designed to change Leu-319 and Leu-320 to Arg and Ser, respectively (65). The resulting DNA fragments were digested with *Nco*I and cloned upstream of the GAL4 DNA binding domain in the pDP18 vector. The point mutations of CREB (37), including those of basic region I (284-R-KR $\rightarrow$ GTT), basic region II (301-R-RKKK $\rightarrow$ RGSRK and 301-R-RKKK $\rightarrow$ GTQEE), and the leucine zippers I and II (L-311, L-318 $\rightarrow$ V,V) were constructed with the oligonucleotide primers 5'-GCTGAAGAAGCAGGATCTA GAGAGGTCCTTAATG-3', 5'-GCAGCTCGAGAGTGTCTGGGA-3', 5'-TCTAGAAAAGAAATATGTGAAATGTTAG-3', and 5'-GGGAAGCAGCT CGAGAGTGTGGTACCAGCAGGAAGAATATGTGAAATGTTAG-3', respectively, and the same 3' primer used to construct the CREB1 5' deletion constructs. The resulting DNA fragments were digested with *Kpn*I-*Bam*HI and cloned into a *Kpn*I-*Bam*HI-digested CREB-VP16 vector. All mutant clones constructed by site-directed mutagenesis were confirmed by DNA sequence analysis.

**Expression and purification of bacterially produced CREB1 and Tax proteins.** The bacterial expression vectors pGEX2T and pQE60 with either Tax or CREB cDNA inserts were transformed into *Escherichia coli* M15. Cultures (400 ml) of *E. coli* were grown to an optical density at 600 nm of 0.6 to 0.8 and induced with 0.1 mM isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) for 3 h. Cells were pelleted, resuspended in buffer A (50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 0.1 mM phenylmethylsulfonyl fluoride), and mildly sonicated, and the debris was pelleted. For GST fusion proteins (64), the supernatant was incubated with 2 ml of glutathione-Sepharose beads for 60 min at 4°C. The beads were then washed five times with 10 ml of buffer A containing 1% Triton X-100 (63). The proteins were eluted by incubation with elution buffer (50 mM Tris-HCl [pH 8.0], 10 mM glutathione) at 4°C. Proteins were dialyzed against protein storage buffer (10 mM Tris-HCl [pH 8.0], 50 mM NaCl, 10% glycerol, 1 mM dithiothreitol [DTT], 0.1 mM phenylmethylsulfonyl fluoride). For 6x His-tagged proteins, bacterial cells were cultured and fractionated under these same conditions except that the cell lysate was incubated with 1 ml of nickel-nitrilotriacetic acid-agarose for 60 min at 4°C. The proteins were eluted with elution buffer (50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM DTT, 1 mM EDTA) containing from 20 to 200 mM imidazole. The proteins were dialyzed against protein storage buffer and kept at  $-80^{\circ}\text{C}$ .

**Gel retardation analysis.** For gel retardation assays, 50 to 100 ng of either bacterially produced GST-CREB or bacterially produced CREB-6x His in either the presence or the absence of bacterially produced Tax-6x His or  $\Delta$ N1Tax-6x His protein was incubated with 1  $\mu\text{g}$  of poly(dI-dC) (Pharmacia) and labeled probe in binding buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 1 mM DTT, 5% glycerol, 50 mM NaCl). The reaction time was for 20 min at room temperature in a 40- $\mu\text{l}$  final volume. Synthetic double-stranded oligonucleotides containing the somatostatin CRE (5'-GGTTCCTCTGGCTGACGTCAGAG AGAGA-3') or HTLV-I LTR 21-bp repeat I (5'-TCCAGCTCCTCAGGCCGT TGACGACAACCCTCAC-3'), 21-bp II (5'-CTCGGGCTAGGCCCTGAC GTGTCCCTGTAA-3'), or 21-bp III (5'-CCAGACTAAGGCTCTGACGTC TCCCCCGGACT-3') were end labeled with [ $\gamma$ - $^{32}\text{P}$ ]ATP, by using T4 polynucleotide kinase. Approximately 0.1 ng of  $^{32}\text{P}$ -labeled DNA (50,000 cpm) was incubated with the CREB and Tax proteins. When competition was performed, unlabeled oligonucleotides in a 50-fold molar excess were added to the reaction mixture. DNA-protein complexes were resolved on a 5% polyacrylamide gel in

TABLE 1. Comparison of HTLV-1 21-bp repeats and consensus CRE sequences

Site	Sequence <sup>a</sup>	
I	A A G G C T C	T G A C G T C T C C C C C C C
II	T A G G C C C	T G A C G T G T C C C C C T
III	C A G G C G T	T G A C G A C A A C C C C T
CRE	C C T A G G C	T G A C G T C A G A G A G A

<sup>a</sup> The nucleotide sequences of the three HTLV-I 21-bp repeats are shown as is the sequence of the somatostatin CRE. The position of domain B in the 21-bp repeats and of the CREB binding site in the somatostatin CRE is indicated.

0.25× TBE (50 mM Tris-borate [pH 8.3], 1 mM EDTA). The gels were dried and autoradiographed with an intensifying screen at -80°C.

**In vitro protein-protein binding.** The bacterially produced Tax-E6K protein was labeled with [ $\gamma$ -<sup>32</sup>P]ATP at the introduced protein kinase A substrate site, by the addition of the protein kinase A catalytic subunit for 15 min at 30°C. A total of 20 to 50  $\mu$ g of GST-CREB, GST-CREB  $\Delta$ N2, or GST-CREB  $\Delta$ C protein was incubated with glutathione-agarose beads for 1 h at 4°C. Approximately 1  $\mu$ g or 300,000 cpm of either Tax-E6K or Tax $\Delta$ N1-E6K labeled proteins was then added with GST-CREB, GST-CREB  $\Delta$ N, or GST-CREB  $\Delta$ C beads in TIB buffer (10% glycerol, 20 mM *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid [HEPES; pH 7.5], 50 mM KCl, 50 mM ZnCl<sub>2</sub>, 2.5 mM MgCl<sub>2</sub>, 0.1% Nonidet P-40, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride) for 1 h at 4°C. The protein-protein complexes were washed five times at 4°C with 10 volumes of TIB buffer. The Tax proteins which remained attached to the beads were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), the gels were dried, and autoradiography was performed.

**Analysis of CREB-VP16 and GAL-Tax protein.** To analyze the expression of the GAL-Tax constructs, each of the constructs was cloned into the pTM1 expression construct downstream of the T7 promoter (14). HeLa cell plates (diameter, 60 mm) were transfected by the calcium phosphate transfection procedure with 10  $\mu$ g of each pTM1 expression construct. Protein expression was induced by infection with a T7 RNA polymerase encoding helper virus at a multiplicity of infection of 5 as previously described (59). Cells were lysed and harvested 24 h later in protein gel loading dye, and cleared whole-cell lysates from  $2 \times 10^5$  cells were used in Western immunoblotting with Tax monoclonal antibody obtained from the AIDS Reagent Repository.

To analyze the expression of the Rous sarcoma virus CREB1-VP16 expression constructs, each of the constructs was transfected into the adenovirus E1A- and E1B-transformed human embryonic kidney cell line 293 (31). At 48 h posttransfection, the cells were lysed and harvested in protein gel loading dye, and the

cleared whole-cell lysates from  $2 \times 10^5$  cells were used in Western immunoblotting with CREB polyclonal antibody (42).

**Transfection and CAT assays.** Jurkat cells were maintained in RPMI and 10% fetal bovine serum with penicillin and streptomycin. Cells were diluted 1:2 in fresh medium on the day prior to transfection, and  $5 \times 10^6$  cells were transfected with 0.2 mg of DEAE-dextran. Cells were harvested after 48 h and one quarter of the cell extract was used for CAT assays (30).

## RESULTS

**Tax stimulates CREB1 binding to nonpalindromic compared with palindromic CRE sites.** The HTLV-I LTR contains three 21-bp repeats, each of which contain sequences known as CRE motifs which have homology to sequences found in cyclic AMP-responsive promoters (23, 54, 61). However, none of the 21-bp repeats contains palindromic CRE sites such as found in the cyclic AMP-regulated somatostatin promoter (51). We compared the binding of bacterially synthesized CREB1 protein to each of the three HTLV-I 21-bp repeats and the somatostatin CRE. CREB1 was the first member of the ATF/CREB family to be identified (50, 51). This 43-kDa protein has been demonstrated to bind to both consensus and nonconsensus CRE elements, and its transcriptional activating properties are regulated by phosphorylation in response to cyclic AMP-dependent protein kinase (28, 37, 50, 51, 74). As shown in Table 1, the nonpalindromic sequences of the CRE site in each of the 21-bp repeats differ from the palindromic sequence found in the somatostatin promoter.

Gel retardation analysis indicated that bacterially produced CREB1 bound weakly to oligonucleotides corresponding to each of the 21-bp repeats (Fig. 1A, lanes 1, 4, and 7). However, it was noted that CREB1 consistently bound better to 21-bp repeat III (Fig. 1A, lane 7). In contrast, with the same concentration of CREB1 protein, a much greater degree of CREB1 binding to the somatostatin CRE was seen (Fig. 1A, lane 10). CREB1 binding was also assayed in the presence of bacterially produced Tax. Tax was able to markedly stimulate CREB1 binding to each of the HTLV-I 21-bp repeats (Fig. 1A, lanes 2, 5, and 8). There was no stimulation of CREB1 binding with the addition of other unrelated proteins such as GST (data not




FIG. 1. Tax stimulates the binding of CREB1 to HTLV-I 21-bp repeats. (A) Oligonucleotides corresponding to HTLV-I 21-bp repeat I (lanes 1 to 3), 21-bp repeat II (lanes 4 to 6), and 21-bp repeat III (lanes 7 to 9) and the somatostatin (somat) CRE (lanes 10 to 12) were end labeled with [ $\gamma$ -<sup>32</sup>P]ATP and used in gel retardation assays. Lanes 1, 4, 7, and 10, 100 ng of bacterial CREB1-6x His alone; lanes 2, 5, 8, and 11, 100 ng of bacterial CREB1-6x His and 100 ng of bacterially expressed Tax-6x His; lanes 3, 6, 9, and 12, 100 ng of Tax-6x His alone. (B) Gel retardation analysis with 21-bp repeat I and either 100 ng of CREB1-6x His alone (lane 1) or 100 ng of TAX-6x His (lane 2). Specific competition of CREB1 binding to 21-bp repeat I was performed by preincubation of either a 50 (lane 3)- or 150 (lane 4)-fold molar excess of unlabeled 21-bp repeat oligonucleotide or similar quantities of unlabeled and B motif-mutated 21-bp repeat oligonucleotides (lanes 5 and 6). (C) Gel retardation analysis with oligonucleotides corresponding to the somatostatin CRE (lanes 1 to 10) were performed in both the absence (lanes 1, 3, 5, 7, and 9) and the presence of 100 ng of Tax (lanes 2, 4, 6, 8, and 10). Either no CREB1 (lanes 1 and 2) or increasing amounts of CREB1 (0.2 ng [lanes 3 and 4], 2 ng [lanes 5 and 6], 20 ng [lanes 7 and 8], and 200 ng [lanes 9 and 10]) were added to the gel retardation assay.




FIG. 2. Tax does not markedly stimulate the binding of CREB2. Oligonucleotides corresponding to HTLV-I 21-bp repeat I (lanes 1 to 3), 21-bp repeat II (lanes 4 to 6), and 21-bp repeat III (lanes 7 to 9) and the somatostatin (somat) CRE (lanes 10 to 12) were end labeled and used in gel retardation analysis. Lanes 1, 3, 7, and 10, 100 ng of bacterially expressed GST-CREB2 alone; lanes 2, 4, 8, and 11, 100 ng of GST-CREB2 and 100 ng of Tax-6x His; lanes 3, 6, 9, and 12, 100 ng of Tax-6x His alone.

shown) or nonfunctional Tax mutants (see below). Tax itself did not bind to any of the HTLV-I 21-bp repeats as has previously been reported (Fig. 1A, lanes 3, 6, 9, and 12). Competition analysis was also performed to demonstrate the specificity of this binding. Wild-type (Fig. 1B, lanes 3 and 4) but not mutated (Fig. 1B, lanes 5 and 6) 21-bp repeat oligonucleotides were able to compete for CREB1 binding to the HTLV-I 21-bp repeats.

It was also interesting that Tax resulted in only minimal stimulation of CREB1 binding to oligonucleotides corresponding to the somatostatin CRE (Fig. 1A, lanes 10 and 11). To further investigate the lack of Tax stimulation of CREB1 binding to the somatostatin CRE, a titration of CREB1 protein ranging from 0.2 to 200 ng was performed (Fig. 1C, lanes 3 to 10). Tax was unable to significantly stimulate the binding of CREB1 to the somatostatin CRE over a wide concentration range of CREB1, and this was confirmed by PhosphorImager scanning (Fig. 1C). Thus, Tax markedly stimulated the binding of CREB1 to the 21-bp repeats but not to a consensus CRE.

**Tax does not stimulate the binding of CREB2 to the HTLV-I 21-bp repeats.** Recently it was reported that Tax was able to stimulate the DNA binding properties of a variety of different DNA-binding proteins, including those containing bZIP binding domains (2, 17, 72). We wished to determine whether Tax was able to stimulate the binding of another bZIP member of the ATF/CREB family of DNA-binding proteins, designated CRE-BP1 or CREB2 (33, 46, 47, 75). CREB2 was produced in bacteria as a GST fusion protein and was purified with glutathione-agarose beads, and its binding properties were tested with oligonucleotides corresponding to both the HTLV-I 21-bp repeats and the somatostatin CRE. At the same protein concentrations as used for CREB1 (Fig. 1), CREB2 bound to each of the HTLV-I 21-bp repeats (Fig. 2, lanes 1, 4, and 7) and to the somatostatin CRE (Fig. 2, lane 10). However, Tax did not markedly stimulate the binding of CREB2 to any of the 21-bp repeats (Fig. 2, lanes 2, 5, and 8) or to the somatostatin CRE (Fig. 2, lane 11). Again, Tax did not bind to any of these DNA probes (Fig. 2, lanes 3, 6, 9, and 12). Thus, Tax stimulated the binding of CREB1 but not CREB2 to the HTLV-I 21-bp repeats. Tax also did not stimulate the binding of other cellular

factors such as AP-2 and PRDII-BF1 that have been demonstrated to bind to the HTLV-I 21-bp repeats (data not shown).

To further investigate the effects of Tax on CREB1 and CREB2 binding to the HTLV-I 21-bp repeats, a variety of additional experiments was performed. To determine the role of differences in the protein concentrations of CREB1 and CREB2 on Tax stimulation of binding to the 21-bp repeats, we performed titrations of both CREB1 and CREB2 on the HTLV-I 21-bp repeat III, with a constant amount of Tax. The titrations of CREB1 and CREB2 were conducted over a range of protein concentrations, from 40 to 200 ng (Fig. 3). The amount of CREB binding was determined by PhosphorImager quantitation of the amount of 21-bp repeat probe bound in both the presence and the absence of Tax. The maximal amount of Tax stimulation of CREB1 binding in this experiment was approximately sevenfold at a CREB1 concentration of 100 ng (Fig. 3A, lanes 5 and 6). At higher CREB1 concentrations, the amount of Tax stimulation was only about twofold (Fig. 3A, lanes 7 and 8). In contrast to the results with CREB1, CREB2 binding to the 21-bp repeats was not affected and in fact it was slightly inhibited by the addition of Tax over a similar protein concentration range (Fig. 3B). Graphs of the amount of CREB1 and CREB2 which were bound to the 21-bp repeats in both the presence and the absence of Tax are shown in Fig. 3C and D.

Next, we wished to further investigate why Tax was unable to stimulate the binding of CREB2 to the 21-bp repeats. The failure of Tax to stimulate the binding of CREB2 was not because CREB2 was expressed as a fusion with GST (Fig. 4A). Though Tax was able to stimulate the binding of CREB1 to 21-bp repeat III (Fig. 4A, lanes 3 and 4), neither the binding of GST-CREB2 (Fig. 4A, lanes 5 and 6) nor increasing amounts of authentic CREB2 generated by cleavage with thrombin (Fig. 4A, lanes 7 to 10) were stimulated by Tax. Coomassie-stained polyacrylamide gels confirmed that thrombin cleavage of GST-CREB2 liberated native CREB2 (data not shown). Finally, we mixed both CREB1 and CREB2 in the same gel retardation reaction mixture with the 21-bp repeat III probe in both the presence and the absence of Tax (Fig. 4B). Tax stimulated the binding of CREB1 to the 21-bp repeat approximately three- to fourfold (Fig. 4B, lanes 3 to 10). However, again there was no stimulation by Tax of the binding of the upper CREB2 doublet to 21-bp repeat III (Fig. 4B, lanes 3 to 10). These experiments further established that Tax would specifically stimulate the binding of CREB1 but not CREB2 to the HTLV-I 21-bp repeats. Studies using on and off rates indicated that Tax stimulated the on rate of CREB binding, as previously demonstrated (data not shown) (72).

**CREB1 but not other leucine zipper proteins directly interact with Tax.** The results of gel retardation analysis indicated that Tax could stimulate the binding of CREB1 to the HTLV-I 21-bp repeats. However, no gel-retarded complex indicative of a stable complex comprising TAX and CREB1 was detectable. Thus, it was not clear whether Tax and CREB1 might be able to directly interact and then dissociate during gel electrophoresis or whether some other mechanism was responsible for Tax stimulation of CREB1 binding. Two approaches to further investigate interactions between Tax and CREB1 were attempted. First, we used *in vivo* analysis with the mammalian two-hybrid system (45), and second, we used direct *in vitro* binding studies to determine whether there was a stable interaction between CREB1 and Tax. For two-hybrid analysis (16), constructs in which Tax was fused at its carboxy terminus to the DNA binding domain of the yeast transcription factor GAL4 were made. Several previous studies have used Tax fusions with GAL4 to demonstrate that Tax contains a weak transcrip-




FIG. 3. Titration of CREB1 and CREB2 binding to the HTLV-I 21-bp repeat. Oligonucleotides corresponding to HTLV-I 21-bp repeat III were end labeled and used in gel retardation analysis with either CREB1 (A and C) or CREB2 (B and D) in either the absence (lanes 1, 3, 5, and 7) or the presence of 100 ng of Tax-6x His (lanes 2, 4, 6, and 8). Increasing amounts of CREB1 (A) or CREB2 (B) (0 ng [lanes 1 and 2], 40 ng [lanes 3 and 4], 80 ng [lanes 5 and 6], or 200 ng [lanes 7 and 8]) were added to each reaction mixture, and the relative amount of each retarded species in both the presence (■) and the absence (□) of Tax was quantitated by PhosphorImager analysis (C and D).

tional activation domain (9, 21, 25). The CREB1 protein was fused at its carboxy terminus to the transcriptional activation domain of the herpesvirus transactivator VP16. A 5x GAL-E1B TATA CAT reporter plasmid (57) was used to assay potential interactions following transfection of these constructs into the T-lymphocyte cell line Jurkat, as illustrated in Fig. 5A (57). Interactions between Tax and CREB in the two-hybrid assay would increase the level of CAT activity because of the effects of positioning the strong acidic activator VP16 near the transcription initiation complex on the E1B promoter (45). Transfections were normalized by the addition of a  $\beta$ -galactosidase control plasmid, and each transfection was repeated at least three times.

The Tax-GAL construct alone gave little increase in gene expression from the reporter construct in the presence of VP16 which was not bound to CREB1 (Fig. 5B, lane 3). This was in agreement with the results of a previous study which showed that a GAL-Tax construct which bound to GAL4 DNA binding sites which lacked the flanking 21-bp repeat sequences was a weak transactivator (9). Likewise, a GAL construct lacking Tax was not activated by CREB1-VP16 (Fig. 5B, lane 2). However, in the presence of both Tax-GAL and CREB1-VP16 con-

structs, gene expression was stimulated approximately 10-fold, indicating a direct and stable interaction between the CREB1 and Tax proteins (Fig. 5B, lane 4). Similar results were seen by switching the GAL4 and VP16 moieties and using CREB1-GAL and Tax-VP16 constructs, but the magnitude of stimulation of gene expression was less than seen with Tax-GAL and CREB1-VP16 constructs (data not shown). For this reason, only Tax-GAL and CREB1-VP16 constructs were further tested. We also assayed whether other proteins containing bZIP domains such as CREB2 or Jun when fused to VP16 were capable of interacting with Tax-GAL. Cotransfection of these bZIP constructs with Tax-GAL and the 5x GAL reporter construct did not increase CAT activity (Fig. 5B, lanes 6 and 8).

It was important to determine whether the failure of the CREB2-VP16 and Jun-VP16 to interact with the Tax-GAL construct could be due to the failure to express these proteins. Also, we wished to assess whether CREB2-VP16 and Jun-VP16 were able to potentially interact with other leucine zipper proteins. As shown in Fig. 5C, we found that CREB2-VP16 was able to interact with the leucine zipper protein Fos by using a Fos-GAL construct (Fig. 5C, lane 2), while it was not able to interact with Tax-GAL (Fig. 5C, lane 3). Jun-VP16 was




FIG. 4. Tax preferentially increases the binding of CREB1 but not CREB2 to the HTLV-I 21-bp repeats. Oligonucleotides corresponding to HTLV-I 21-bp repeat III were end labeled and used in gel retardation analysis with either CREB1 or CREB2 in separate reactions (A) or combined (B) in both the absence (lanes 1, 3, 5, 7, and 9) and the presence (lanes 2, 4, 6, 8, and 10) of 100 ng of Tax (A and B). (A) Gel retardation assay with HTLV-I 21-bp repeat III with no added CREB1 (lanes 1 and 2), 200 ng of CREB1 (lanes 3 and 4), 100 ng of GST-CREB2 (lanes 5 and 6), and either 100 ng (lanes 7 and 8) or 200 ng (lanes 9 and 10) of thrombin-cleaved GST-CREB2. (B) Gel retardation assay with 100 ng of HTLV-I 21-bp III with no added CREB1 (lanes 1 and 2), 200 ng of CREB2 alone (lanes 3 and 4), 200 ng of CREB2 and 40 ng of CREB1 (lanes 5 and 6), 200 ng of CREB2 and 80 ng of CREB1 (lanes 7 and 8), and 200 ng of both CREB2 and CREB1 (lanes 9 and 10).

also unable to interact with Tax-GAL (Fig. 5C, lane 4), while it was able to strongly interact with Fos-GAL (Fig. 5C, lane 6). In this same experiment CREB1-VP16 strongly interacted with Tax-GAL (Fig. 5C, lane 5). Western blot analysis indicated the stable expression of these proteins following transfection (data not shown). Thus, the mammalian two-hybrid system demonstrated interactions between Tax and CREB1 but not between Tax and other bZIP proteins, including CREB2 and Jun.

**The amino terminus of Tax is critical for interactions with CREB1.** Extensive mutagenesis of the Tax protein has indicated that the multiple regions of this protein are required for transcriptional activation (60, 64). Two studies which have investigated the transactivation properties of GAL-Tax fusion proteins when bound to GAL4 binding sites have demonstrated that Tax mutants which are defective for transactivation in this assay were also defective for activation of the HTLV-I LTR, indicating the relevance of this system for studying Tax function (21, 25). To determine which regions of Tax were involved in interactions with CREB1, both deletion and oligonucleotide-directed mutagenesis of the Tax protein were performed. A schematic of the Tax mutants used in this study is shown in Fig. 6A. Three carboxy-terminal truncations of Tax, each of which was fused to the DNA binding domain of GAL4, were tested for their abilities to interact with CREB1-VP16 and increase gene expression from the 5x GAL reporter con-




FIG. 5. Tax interacts with CREB1 in the mammalian two-hybrid system. (A) Schematic diagram of the mammalian two-hybrid system, including the 5x GAL-E1b TATA CAT reporter construct and the GAL-Tax and CREB-VP16 fusion proteins. (B) Percent CAT conversions for the 5x GAL reporter construct transfected into Jurkat cells with GAL-VP16 (74%) (lane 1), GAL and CREB1-VP16 (1.8%) (lane 2), Tax-GAL and VP16 (1.7%) (lane 3), Tax-GAL and CREB1-VP16 (18%) (lane 4), GAL and CREB2-VP16 (1.6%) (lane 5), Tax-GAL and CREB2-VP16 (1.4%) (lane 6), GAL and *jun*-VP16 (1.6%) (lane 7), or Tax-GAL and *jun*-VP16 (1.4%) (lane 8). (C) Percent CAT conversions for the 5x GAL reporter construct transfected into Jurkat cells for Fos-GAL (7.2%) (lane 1), Fos-GAL and CREB2-VP16 (45%) (lane 2), Tax-GAL and CREB2-VP16 (6.3%) (lane 3), Tax-GAL and *jun*-VP16 (6.5%) (lane 4), Tax-GAL and CREB1-VP16 (61%) (lane 5), and Fos-GAL and *jun*-VP16 (58%) (lane 6).

struct. Two of these carboxy-terminal truncations, Tax $\Delta$ C1-GAL and Tax $\Delta$ C2-GAL, which deleted either 16 or 36 amino acids, respectively, were each able to interact with CREB1-VP16 (Fig. 6B, lanes 5 and 7). However, a further carboxy-terminal deletion of Tax, Tax $\Delta$ C3-GAL, which removed a total of 56 amino acids, was not able to interact with CREB1-VP16 (Fig. 6B, lane 9). Truncations of the amino terminus of Tax were also tested. Two amino-terminal truncations of Tax, Tax $\Delta$ N1-GAL and Tax $\Delta$ N2-GAL, which deleted either 93 or 136 amino acids, respectively, were both unable to interact with CREB1-VP16 and increase gene expression from the reporter construct (Fig. 6B, lanes 11 and 13).

In addition to amino- and carboxy-terminal truncations of Tax, we also tested the activity of three previously described site-directed mutants in Tax designated M1, M22, and M47, which were reported to have differential abilities to activate either HTLV-I or HIV-1 CAT constructs (64). The M1 mutant, which changed the histidine at amino acid 3 of Tax to serine, and the M47 mutant, which changed two leucine residues at 319 and 320 of Tax to arginine and serine, were reported to be very defective for HTLV-I activation but yet were active for HIV-1 activation (64). In contrast the M22 mutation,




FIG. 6. Mutagenesis of Tax defines domains which interact with CREB1. (A) Schematic of Tax proteins fused to the DNA binding domain of GAL4, including three carboxy-terminal truncations ( $\Delta$ C1,  $\Delta$ C2, and  $\Delta$ C3), two amino-terminal truncations ( $\Delta$ N1 and  $\Delta$ N2), and three site-directed mutants (M1, M22, and M47), are indicated. (B) Either wild-type or truncations of Tax fused to the DNA binding domain of GAL4 were transfected with CREB1 (CR1) proteins fused to VP16 and a 5x GAL4 reporter construct. The percent CAT conversion is shown

which changed glycine and leucine residues at amino acids 137 and 138 of Tax to alanine and serine, was reported to partially activate the HTLV-I LTR but not the HIV-1 LTR. Thus, it was suggested that these mutants might have altered specificities for activation of CREB and NF- $\kappa$ B binding sites (64). The Tax M1-GAL construct was able to interact, though at reduced levels, with CREB1-VP16 (Fig. 6C, lane 6), while the M22 and M47 mutants were found to be defective for interactions with CREB1-VP16 (Fig. 6C, lanes 8 and 10). All three of these mutants were found to be defective for activation of HTLV-I LTR CAT gene expression following transfection into Jurkat cells (data not shown). The reason for the differences in the phenotype of these Tax mutants on HTLV-I gene expression compared with that of a previous study (64) could not be determined, but altered phenotypes of several similar types of Tax mutants have been noted (60). However, the results of our mutagenesis of the Tax protein, in agreement with the results of other studies (60, 64), indicated that the carboxy terminus of Tax in contrast to the remainder of the protein was dispensable for activation of HTLV-I gene expression and interactions with CREB1.

With these different Tax constructs, it was critical to determine whether they were able to express equivalent levels of Tax protein. The Tax-GAL constructs were cloned downstream of the T7 promoter in the expression vector pTM1 (14). Following transfection of these constructs into HeLa cells, the cells were infected with a recombinant vaccinia virus which expressed T7 polymerase (14). Vaccinia virus expression constructs have previously been used to study the stability and function of mammalian transcription factors (39). Cellular extracts were prepared, and Western blot analysis was performed with a monoclonal antibody directed against the C-terminal portion of Tax (between amino acids 330 and 353). As shown in Fig. 6D, roughly equivalent amounts of wild-type Tax and mutants M1, M22, M47, and  $\Delta$ N1 were produced (Fig. 6D, lanes 1 to 5). There was a somewhat reduced expression of the  $\Delta$ N2 Tax mutant (Fig. 6D, lane 6). Since the Tax monoclonal antibody would not detect C-terminal truncations of Tax, we also placed the wild-type GAL-Tax and the  $\Delta$ C3 mutant constructs into pTM1 and attached the 12-amino-acid influenza virus hemagglutinin epitope, which reacts with the commercially available monoclonal antibody 12CA5. The  $\Delta$ C3 Tax protein was also expressed at levels equivalent to that of wild-type Tax (data not shown). These results indicated that the two

for the 5x GAL reporter construct with GAL and CR1-VP16 alone (2.6%) (lane 1), Tax-GAL and VP16 (1.4%) (lane 2), Tax-GAL and CR1-VP16 (38%) (lane 3), Tax-GAL $\Delta$ C1 and VP16 (1.5%) (lane 4), Tax-GAL $\Delta$ C1 and CR1-VP16 (11%) (lane 5), Tax $\Delta$ C2-GAL and VP16 (1.2%) (lane 6), Tax $\Delta$ C2-GAL and CR1-VP16 (4.0%) (lane 7), Tax $\Delta$ C3-GAL and VP16 (1.3%) (lane 8), Tax $\Delta$ C3-GAL and CR1-VP16 (1.3%) (lane 9), Tax $\Delta$ N1-GAL and VP16 (0.9%) (lane 10), Tax $\Delta$ N1-GAL and CR1-VP16 (0.8%) (lane 11), Tax $\Delta$ N2-GAL and VP16 (0.8%) (lane 12), Tax $\Delta$ N2-GAL and CR1-VP16 (1.4%) (lane 13), and GAL-VP16 (89%) (lane 14). (C) Point mutants in Tax were assayed, and the percent CAT conversion is shown for the 5x GAL reporter with GAL-VP16 (83%) (lane 1), GAL and CR1-VP16 (1.5%) (lane 2), Tax-GAL and VP-16 (1.3%) (lane 3), Tax-GAL and CR1-VP16 (20%) (lane 4), Tax M1-GAL and VP16 (1.3%) (lane 5), Tax M1-GAL and CR1-VP16 (11%) (lane 6), Tax M22-GAL and VP16 (1.3%) (lane 7), Tax M22-GAL and CR1-VP16 (1.8%) (lane 8), Tax M47-GAL and VP16 (1.7%) (lane 9), and Tax M47-GAL and CR1-VP16 (1.7%) (lane 10). (D) A variety of the Tax-GAL constructs tested in two-hybrid analysis for panels B and C were cloned downstream of the T7 promoter in the expression vector pTM1 and transfected into HeLa cells and then infected with a recombinant virus which expresses T7 polymerase. Western blot analysis was performed on the cellular extracts with a monoclonal antibody directed against the C terminus of Tax for Tax-GAL (lane 1), Tax-M1GAL (lane 2), Tax-M22GAL (lane 3), Tax-M47 GAL (lane 4), Tax- $\Delta$ N1 GAL (lane 5), and Tax- $\Delta$ N2 GAL (lane 6). Lane 7, mock infection.




FIG. 7. Mutagenesis of CREB1 defines domains which interact with Tax. (A) Schematic of fusion proteins of CREB1 with the activation domain of VP16 including deletions of the CREB1 carboxy terminus, (CREBΔC), deletions of the amino terminus, (CREBΔN1 and CREBΔN2), and oligonucleotide-directed mu-

critical Tax deletion mutants used in this study, ΔN1 and ΔC3, in addition to the Tax point mutants were expressed at levels equivalent to that of wild-type Tax.

**The bZIP region of CREB1 is critical for interaction with Tax.** The activity of the 43-kDa CREB protein is mediated by protein kinase A phosphorylation of a serine residue at amino acid 133 (28, 29, 50, 74). CREB1 also contains a leucine zipper domain near its carboxy terminus, with four leucine residues spaced seven residues apart preceded by a region of basic amino acids (28, 37). The leucine zipper functions in CREB1 dimerization, which has been demonstrated to be critical for its DNA binding, while the basic residues are required for DNA binding but not dimerization (13). We wished to map the domains in CREB1 which were required for interactions with Tax by testing a variety of amino- and carboxy-terminal truncations in addition to several site-directed mutants (Fig. 7A). Each of these CREB1 mutants was fused to the activation domain of VP16 and then tested for interactions with Tax by the mammalian two-hybrid system. Two amino-terminal truncations of CREB1, CREBΔN1-VP16 and CREBΔN2-VP16, which deleted either 136 or 274 amino acids, respectively, were each able to directly interact with Tax-GAL in the two-hybrid system (Fig. 7B, lanes 7 and 9). Thus, the amino terminus of CREB1, including the site for phosphorylation by protein kinase A, was not critical for interactions with Tax. A carboxy-terminal truncation of CREB1, CREBΔC-VP16, which deleted between amino acids 267 and 341, did not interact with Tax (Fig. 7B, lane 5). Since this mutant removed the basic and leucine zipper regions of CREB1, it suggests that the basic and leucine zipper regions of CREB1 were likely targets for interaction with Tax.

To better define the interactions of CREB1 with Tax, site-directed mutations were constructed in either of two basic amino acid regions in CREB1 or the adjacent leucine zipper region (28, 33, 37). Each of these CREB1 mutants was then fused to the VP16 activation domain and tested for its ability to interact with Tax-GAL. A CREB1 basic region mutant, CREB (b1 mut), which changed amino acids 284 to 286, failed to interact with Tax-GAL (Fig. 7C, lane 5). Likewise, two different sets of mutations in another portion of the basic domain of CREB1 between amino acids 301 and 305, CREB (b2 mut) and CREB (b3 mut), were also defective in their abilities to interact with Tax (Fig. 7C, lanes 7 and 9). Finally, we tested whether mutation of two of the four leucine residues in the

tants of either the basic region including CREB (b1 mut), CREB (b2 mut), and CREB (b3 mut) or the leucine zipper, CREB (zip mut). (B) Truncations of CREB1 were assayed and the percent CAT conversion of the 5x GAL reporter construct is shown for transfections with Tax-GAL and VP16 (3.1%) (lane 1), GAL and CR1-VP16 (2.2%) (lane 2), Tax-GAL and CR1-VP16 (88%) (lane 3), GAL and CR1ΔC-VP16 (1.7%) (lane 4), Tax-GAL and CR1ΔC-VP16 (1.3%) (lanes 5), GAL and CR1ΔN1-VP16 (2.4%) (lane 6), Tax-GAL and CR1ΔN1-VP16 (84%) (lane 7), GAL and CR1ΔN2-VP16 (2.7%) (lane 8), and Tax-GAL and CR1ΔN2-VP16 (93%) (lane 9). (C) Site-directed mutants of the bZIP domain of CREB were assayed and the percent CAT conversion is shown for Tax-GAL and VP16 (1.5%) (lane 1), GAL and CR1-VP16 (2.2%) (lane 2), Tax-GAL and CR1-VP16 (83%) (lanes 3), GAL and CR1 (b1 mut)-VP16 (1.3%) (lane 4), Tax-GAL and CR1 (b1 mut)-VP16 (1.5%) (lane 5), GAL and CR1 (b2 mut)-VP16 (1.1%) (lane 6), Tax-GAL and CR1 (b2 mut)-VP16 (1.5%) (lane 7), GAL and CR1 (b3 mut)-VP16 (6%) (lane 8), Tax-GAL and CR1 (b3 mut)-VP16 (1.1%) (lane 9), GAL and CR1 (zip mut)-VP16 (1.2%) (lane 10), Tax-GAL and CR1 (zip mut)-VP16 (2.0%) (lane 11), and GAL + VP16 (92%) (lane 12). (D) A variety of CREB1-VP16 constructs tested in two-hybrid analysis for panels B and C were transfected into 293 cells, and the cellular extract obtained was used in Western blot analysis with rabbit polyclonal antibody directed against CREB1 for CR1-VP16 (lane 1), CR1ΔC-VP16 (lane 2), CR1ΔN1-VP16 (lane 3), CR1ΔN2-VP16 (lane 4), CR1 (zip mut)-VP16 (lane 5), and CR1(b2 mut)-VP16 (lane 6). Lane 7, mock infection.






FIG. 8. N-terminal truncations of Tax do not interact with CREB1. (A) Oligonucleotides corresponding to 21-bp repeat I (lane 1) were end labeled and used in gel retardation with 50 ng of GST-CREB and 100 ng of Tax-6x His (lane 2), 50 ng of GST-CREB and 100 ng of Tax $\Delta$ N1-6x His (lane 3), or 100 ng of Tax-6x His alone (lane 4). Either wild-type Tax-6x His (B) or Tax $\Delta$ N1-6x His (C) labeled with  $^{32}$ P was subjected to PAGE either alone (lane 1) or following incubation with agarose beads containing GST-CREB (lane 2), GST-CREB $\Delta$ N1 ( $\Delta$ 4-136) (lane 3), or GST-CREB $\Delta$ C (lane 4). The positions of the molecular weight markers (in thousands) are shown.

leucine zipper of CREB1, CREB (zip mut), resulted in a protein with altered interactions for Tax. This mutant did not interact with Tax-GAL (Fig. 7C, lane 11). Thus, mutation of either the basic domain or the leucine zipper of CREB1 prevented its ability to interact with Tax.

With these different CREB VP-16 expression constructs, it was critical to determine whether any of the CREB1 mutations altered the stability of the proteins following transfection. A variety of the CREB1-VP16 constructs used for Fig. 7B and C were transfected into 293 cells, which have a very high transfection efficiency, and Western blot analysis was performed with CREB1 antibody. Two-hybrid analysis with Tax-GAL was performed on a portion of each of these samples, and the results corresponded with those obtained for Fig. 6 and 7 with Jurkat cells (data not shown). Roughly equivalent levels of protein were detected with the wild-type CREB1-VP16 construct (Fig. 7D, lane 1) and a variety of N-terminal deletion mutants (Fig. 7D, lanes 3 and 4) as well as CREB-VP16 constructs with substitutions of leucine zippers 1 and 2 (zip mut) (Fig. 7D, lane 5) and a portion of the CREB1 basic domain (b2mut) (Fig. 7D, lane 6). The only mutant that expressed to levels different from those of wild-type CREB1-VP16 constructs was the CREB $\Delta$ C-VP16 construct (Fig. 7D, lane 2), whose expression level was higher than that of the wild-type construct. This mutant failed to interact with Tax-GAL (Fig. 7B). These experiments indicated that the CREB-VP16 constructs expressed similar levels of protein when transfected into cells.

**Wild-type but not mutant Tax proteins directly interact with CREB1 in vitro.** Since the results of the two-hybrid analysis with Tax and CREB1 expression constructs suggested that these proteins were capable of direct interactions, we attempted to correlate these results by in vitro interaction studies. First, we tested whether an amino-terminal deletion mutant of Tax, Tax $\Delta$ N1, that was unable to interact with CREB1 in two-hybrid analysis could stimulate the binding of CREB1 to the HTLV-I 21-bp repeat. By gel retardation analysis, the wild-type Tax protein stimulated the binding of CREB1 to the 21-bp repeat (Fig. 8A, lane 2), while the Tax $\Delta$ N1 mutant did not stimulate CREB1 binding (Fig. 8A, lane 3). Thus, a Tax mutant which did not interact with CREB1 in two-hybrid analysis also did not stimulate CREB1 binding in vitro.

Next, we wished to address whether either wild-type or mutant Tax proteins could directly interact with CREB1, even

though a gel-retarded species consistent with a complex composed of both Tax and CREB1 was not detected.  $^{32}$ P-labeled Tax protein was incubated with either GST-CREB1 or GST fusions with CREB1 mutants which deleted either its amino terminus (CREB $\Delta$ N1) or its carboxy terminus (CREB $\Delta$ C). Tax bound strongly to GST-CREB1 (Fig. 8B, lane 2) and equally well to the GST-CREB $\Delta$ N1 protein which contained a deletion between amino acids 4 and 136 (Fig. 8B, lane 3). However, Tax was unable to bind to the GST-CREB $\Delta$ C mutant protein which deleted between amino acids 267 and 341, including both the basic and the leucine zipper domains (Fig. 8B, lane 4). In contrast to the results with the wild-type Tax protein, the amino-terminal truncated and  $^{32}$ P-labeled Tax $\Delta$ N1 protein was unable to bind to GST fusions with either wild-type CREB1 or amino- and carboxy-terminal truncations of CREB1 (Fig. 8C, lanes 2 to 4). These results indicate that Tax and CREB1 specifically interacted, using both in vitro and in vivo assays. Furthermore, the bZIP protein of CREB1 and the majority of Tax excluding its carboxy terminus were critical for this interaction.

## DISCUSSION

The mechanism by which the HTLV-I transactivator Tax is able to activate viral and cellular gene expression is not fully known. Tax is unable to bind directly to DNA (3, 25, 27); thus, its mode of action likely involves either direct or indirect interactions with cellular transcription factors (48). Tax is able to activate the HTLV-I LTR through three regulatory elements known as 21-bp repeats each of which contains nonpalindromic CREs (6, 23, 54, 61). In addition, Tax has been demonstrated to activate gene expression from both the HIV-I LTR (5, 60, 64, 66) and the IL-2 receptor  $\alpha$  (5, 10, 43, 60) through NF- $\kappa$ B binding sites and the *c-fos* promoter (19–21) through the serum response element binding factor p67<sup>SRF</sup>. These results indicate that Tax is able to modulate the binding or transcriptional activating properties of multiple cellular transcription factors to facilitate increases in gene expression.

A number of studies have indicated that Tax can directly interact with specific cellular transcription factors that bind to promoter elements that are activated by Tax. Cellular extracts containing Tax have been demonstrated to contain increased NF- $\kappa$ B binding activity in gel retardation analysis (43, 44). In fact, immunoprecipitation experiments indicate that Tax and

both the p105 and the p100 forms of NF- $\kappa$ B form a stable intracellular complex (5, 35, 36). Mutagenesis of one of the cytoplasmic inhibitors of NF- $\kappa$ B nuclear localization, I $\kappa$ B  $\gamma$ , which contains the C-terminal portion of p105, indicated that the ankyrin repeats of this protein were the site of interaction with Tax (36). Thus, one mode of Tax activation of promoters containing NF- $\kappa$ B binding sites may be direct interaction with I $\kappa$ B  $\gamma$  or other members of the I $\kappa$ B family, resulting in the translocation of the p65 form of NF- $\kappa$ B from the cytoplasm to the nucleus, with resultant activation of gene expression.

In addition to effects on the cellular localization of NF- $\kappa$ B, Tax has been shown to activate gene expression from the *c-fos* promoter through the serum response regulatory element (18, 19). The serum response regulatory element contains a region of dyad symmetry with a CARG box which binds a factor designated p67<sup>srf</sup> (20). Normally, p67<sup>srf</sup> can form a complex with a mitogen-inducible factor, p62<sup>icf</sup>, which enhances p67<sup>srf</sup> binding. Tax has been demonstrated to directly bind to p67<sup>srf</sup> in vitro and directly interact with p67<sup>srf</sup> in the mammalian two-hybrid system (20). Mutagenesis experiments with p67<sup>srf</sup> indicate that the carboxy-terminal half of p67<sup>srf</sup>, which lacks domains for DNA binding, dimerization, and ternary complex formation with p62<sup>icf</sup>, was sufficient for interaction with Tax.

Tax has also been demonstrated to stimulate the binding of a variety of DNA-binding proteins containing leucine zippers, including members of the ATF/CREB family to the HTLV-I 21-bp repeats (2, 3, 68, 72, 75–77). However, since the activation properties of Tax for both viral and cellular promoters is restricted, the functional significance of these findings remains to be determined. In this study, we wished to address questions concerning the mechanism by which Tax activates gene expression of the HTLV-I LTR. Though a nonpalindromic CRE is present within each 21-bp repeat, questions have remained about the role of CREB in *tax* activation of the HTLV-I LTR. It is not clear how the elements flanking the CRE in the 21-bp contribute to Tax induction, though a recent study suggests that these elements specify an extended binding site for a protein complex comprising both CREB and Tax (53). However, both our *in vivo* and our *in vitro* analyses suggest that the extended binding site is not essential for Tax and CREB interaction. Also, if CREB is important for activation of HTLV-I, why is Tax unable to activate other promoters containing CRE sites? Does Tax stably interact with one or a variety of members of the ATF/CREB family? What domains in the Tax and CREB proteins are required for their interaction, and is this interaction critical for Tax activation of HTLV-I gene expression?

We found that Tax stimulated the DNA binding of CREB1 but not CREB2 to the HTLV-I 21-bp repeats, indicating specificity for Tax function. This is in contrast to several other studies which indicated that Tax could stimulate the binding of a variety of other leucine zipper DNA-binding proteins (2, 72). Furthermore, though Tax stimulated the binding of CREB1 to the 21-bp repeat, it did not stimulate the binding of CREB1 to the somatostatin CRE at similar protein concentrations. This may be due to the fact that the HTLV-I 21-bp repeats contain a nonconsensus CRE in contrast to the consensus CRE found in the somatostatin CRE or to the effects of the GC-rich sequences found in the A and C domains of the 21-bp repeats which may be critical for Tax function. CREB1 bound with a higher affinity to the consensus compared with a nonconsensus CRE site. Thus, the restriction of *Tax* activation of promoters containing consensus CRE sites may in part be determined by the endogenous cellular concentration of CREB1 protein. CREB1 may be present in concentrations which allow stimulation of its binding to the 21-bp repeat by Tax but yet be

present in high enough quantities that do not allow Tax stimulation of CREB1 binding to other promoters with CRE sites (24).

We demonstrated, with *in vitro* binding assays, that Tax was able to associate directly with CREB1. Several mutants that have previously been demonstrated to inactivate the transcriptional activating properties of either Tax or CREB1 in transfection assays were unable to interact *in vitro*, suggesting a functionally significant interaction (60, 64). The relevance of these *in vitro* interactions between CREB1 and Tax were extended with the mammalian two-hybrid system. The specificity of these interactions was tested by demonstrating that Tax could directly interact with CREB1 but not CREB2 or a variety of other bZIP proteins such as AP-4, Jun, and Fos. Consistent with these findings, it was demonstrated that the adenovirus E1A protein, but not Tax, activated gene expression from a reporter construct which bound a CRE-BP1 or CREB2 fusion protein (46). Thus, our studies correlated both *in vitro* and *in vivo* studies and demonstrated that Tax specifically interacted with CREB1.

Deletion and oligonucleotide-directed mutants of Tax and CREB1 were used to define domains involved in interaction between these proteins, by two-hybrid analysis. Tax proteins containing deletions of the carboxy terminus were able to interact with CREB1, while Tax proteins containing amino-terminal deletions were unable to interact with CREB1. Three previously characterized point mutations in Tax, designated M1, M22, and M47, which were grouped according to their differential activation phenotype for either CREB binding sites (M1 and M47) and NF- $\kappa$ B binding sites (M22), were also tested for their abilities to interact with CREB1 (64). We found that the M1 Tax mutant was able to interact with CREB1, though to a lesser degree than wild-type Tax. Both the M22 and M47 Tax mutants were unable to interact with CREB. Transfection of M1, M22, or M47 Tax mutants along with an HTLV-I CAT reporter construct indicated that each of these mutants was very defective for activation of HTLV-I gene expression. The failure of the M1 mutant to transactivate the HTLV-I LTR, yet partially interact with CREB1 in two-hybrid analysis when fused to GAL4, may be explained by potential effects of this mutation on interrupting Tax nuclear localization (64, 65), which may be compensated by the GAL4 nuclear localization signal, or perhaps disrupting a domain in Tax required for either transcriptional activation or interaction with other transcription factors. A previously characterized mutant, d320, was also found to directly interact with CREB in gel retardation analysis, yet it failed to activate HTLV-I LTR gene expression in transfection experiments (68). Both point mutants and deletion mutants of Tax indicated that the majority of the Tax protein excluding its carboxy terminus was critical for both transactivation of HTLV-I LTR and interaction with CREB1. Similar results have been obtained using both wild-type and mutated GAL-Tax (21, 25) and Tax (60, 64) constructs.

Mutagenesis was also performed to determine the region of CREB1 that was responsible for interaction with Tax in two-hybrid analysis. The effects seen with different Tax and CREB1 proteins in this assay were not due to differences in protein stability as determined by Western blot analysis. Amino-terminal truncations of CREB1 that deleted domains that have been demonstrated to be important for transcriptional activation were still able to interact with Tax. However, carboxy-terminal deletions of the CREB1 protein were unable to interact with Tax. This suggested that the bZIP region of CREB1 was involved in interactions with Tax. Oligonucleotide-directed mutation of two portions of the basic region or the leucine zipper

region of CREB1 eliminated interactions with Tax. A recent study indicated that three residues (282 to 284) in the basic domain of CREB1 were sufficient to confer recognition specificity by Tax (1). A similar mutant, CREB (b1 mut), in this study was defective for interactions with Tax in the two-hybrid analysis. However, other basic and leucine zipper mutants of CREB1 were also defective for interactions with Tax. The failure to detect these other regions was likely due to the fact that fusions of CREB and ATF1 were used in the previous study and these proteins have a very high degree of homology in other portions of their bZIP domains (1).

The ability to perform *in vivo* analysis of CREB1 and Tax interactions rather than gel retardation assays exclusively allows one to more clearly elucidate potential interactions. For instance, mutations of the CREB1 leucine zipper will inhibit its dimerization and subsequent DNA binding properties (13). Likewise, mutations of the CREB1 basic domain will inhibit its DNA binding properties (13). Thus, it becomes difficult to determine the domains required for CREB1 interaction with Tax by gel retardation analysis if in fact these same domains are required for CREB1 binding to DNA. The two-hybrid assay used in this study offers many advantages to study interactions between CREB1 and Tax. In summary, our *in vivo* and *in vitro* results indicate that in the absence of CREB1 binding to its cognate DNA site, both its basic and its leucine zipper regions were critical for interactions with Tax.

The direct interaction between the CREB1 and Tax proteins demonstrated by both *in vivo* and *in vitro* studies could potentially result in Tax-mediated increases in CREB1 dimerization and subsequent increases in CREB1 binding to the 21-bp repeats. The failure in our study to identify complexes composed of both Tax and CREB1 by gel retardation analysis (1, 68, 76, 77) has been noted in several other studies (2, 17, 72). This may be due to the unstable nature of the CREB1 and Tax complex with dissociation during PAGE. Tax could potentially interact with two CREB proteins via their basic domains or leucine zipper. In this latter model, Tax may be in direct contact with the CRE binding site in conjunction with a CREB dimer. An alternative but less likely model would be that a heterodimer composed of a CREB1 monomer and Tax could also potentially bind to the CRE. Finally, a transient interaction between CREB1 and Tax which either induces CREB1 dimerization and/or directly increases the rate of CREB DNA binding is possible. Both structural and mutagenesis studies of the CREB1 and Tax proteins are under way in an attempt to address these possibilities.

The ability of Tax to modulate CREB1 binding is likely a key feature in the activation of HTLV-I gene expression. However, it is likely that Tax interactions with either TFIID or general transcriptional factors will also be important for activation of HTLV-I gene expression (8). Thus, Tax may have several cellular targets which are involved in the activation of HTLV-I gene expression and serve as an adapter molecule which may serve as a bridge between the CREB1 and the TFIID complex. Tax, like the adenovirus E1A protein which binds to ATF-2, can interact with a member of the ATF/CREB family (45). Other HTLV-I binding proteins such as Ets and cellular factors binding to the A and C motifs flanking the CRE in the 21-bp repeats may also be important for Tax activation (58). However, an understanding of the mechanism by which Tax mediates the interactions and binding properties of CREB to the HTLV-I 21-bp repeats will provide important insights into the properties of this interesting viral transactivator protein. Our study demonstrates that CREB1 and Tax interact *in vivo* and provide a convenient means to carefully elucidate the protein domains involved in the interaction between an impor-

tant viral transactivator and a critical cellular transcription factor.

#### ACKNOWLEDGMENTS

The first two authors contributed equally to this work.

We thank Ty Lawrence and Elizabeth Folta for manuscript preparation.

This work was supported by a grant from the Council of Tobacco Research.

#### REFERENCES

- Adya, N., L.-J. Zhao, W. Huang, I. Boros, and C.-Z. Giam. 1994. Expansion of CREB's DNA recognition specificity by TAX results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. *Proc. Natl. Acad. Sci. USA* **91**:5642-5646.
- Armstrong, A. P., A. A. Franklin, M. N. Henbogaard, H. A. Giebler, and J. K. Nyborg. 1993. Pleiotropic effect of the human T-cell leukemia virus Tax protein on the DNA binding activity of eukaryotic transcription factors. *Proc. Natl. Acad. Sci. USA* **90**:7303-7307.
- Beimling, P., and K. Moelling. 1992. Direct interaction of CREB protein with 21 bp Tax-response elements of HTLV-I LTR. *Oncogene* **7**:257-262.
- Beraud, C., G. L. Platet, Y. Michal, and P. Jalinot. 1991. Binding of the HTLV-I Tax 1 transactivator to the inducible 21 bp enhancer is mediated by the cellular factor HEB1. *EMBO J.* **10**:3795-3803.
- Beraud, C., S. C. Sun, P. Ganchi, D. W. Ballard, and W. C. Greene. 1994. Human T-cell leukemia virus type I Tax associates with and is negatively regulated by the NF- $\kappa$ B p100 gene product: implications for viral latency. *Mol. Cell. Biol.* **14**:1374-1382.
- Brady, J., K. T. Jeang, J. Duvall, and G. Khoury. 1987. Identification of p40<sup>ox</sup>-responsive regulatory sequences within the human T-cell leukemia virus type I long terminal repeat. *J. Virol.* **61**:2175-2181.
- Cann, A. J., J. D. Rosenblatt, W. Wachsman, N. P. Shah, and I. S. Y. Chen. 1985. Identification of the gene responsible for human T-cell leukemia virus transcriptional regulation. *Nature (London)* **318**:571-574.
- Caron, C., R. Rousset, C. Beraud, V. Moncollin, J. M. Egly, and P. Jalinot. 1993. Functional and biochemical interaction of the HTLV-I Tax 1 transactivator with TBP. *EMBO J.* **12**:4269-4278.
- Connor, L. M., M. N. Oxman, J. N. Brady, and S. J. Marriott. 1993. Twenty-one base pair repeat elements influence the ability of a GAL4-Tax fusion protein to transactivate the HTLV-I long terminal repeat. *Virology* **195**:569-577.
- Cross, S. L., M. B. Feinberg, J. B. Wolf, N. J. Holbrook, F. Wong-Staal, and W. J. Leonard. 1987. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. *Cell* **49**:47-56.
- Cullen, B. R. 1992. Mechanism of action of regulatory proteins encoded by complex retroviruses. *Microbiol. Rev.* **56**:375-394.
- Diep, A., C. Li, I. Klisak, T. Mohandas, R. S. Sparkes, R. Gaynor, and A. J. Lusis. 1991. Assignment of the gene for cyclic AMP-response element binding protein 2 (CREB2) to human chromosome 2q24.1-q32. *Genomics* **11**:1161-1163.
- Dwarki, V. J., M. Montminy, and I. M. Verma. 1990. Both the basic region and the leucine zipper domain of the cyclic AMP response element binding (CREB) protein are essential for transcriptional activation. *EMBO J.* **9**:225-232.
- Elroy-Stein, O., T. R. Fuerst, and B. Moss. 1989. Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. *Proc. Natl. Acad. Sci. USA* **86**:6126-6130.
- Felber, B. K., H. Paskalis, D. Kleinman-Ewing, F. Wong-Staal, and G. N. Pavlakis. 1985. The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. *Science* **229**:54-58.
- Fields, S., and O. Song. 1989. A novel genetic system to detect protein-protein interactions. *Nature (London)* **340**:245-246.
- Franklin, A. A., M. F. Kubik, M. N. Uittenbogaard, A. Brauweiler, P. Utaincharoen, M.-A. H. Matthews, W. S. Dynan, J. P. Hoeffler, and J. K. Nyborg. 1993. Transactivation by the human T-cell leukemia virus tax protein is mediated through enhanced binding of activating transcription factor-2 (ATF-2) ATF-2 response and cAMP element-binding protein (CREB). *J. Biol. Chem.* **268**:21225-21231.
- Fujii, M., T. Niki, T. Mori, T. Matsuda, M. Matsui, N. Nomura, and M. Seiki. 1991. HTLV-I Tax induces expression of various immediate early serum responsive genes. *Oncogene* **6**:2349-2352.
- Fujii, M., P. Sassone-Corsi, and I. M. Verma. 1988. c-fos promoter transactivation by the tax1 protein of human T-cell leukemia virus type I. *Proc. Natl. Acad. Sci. USA* **85**:8526-8530.
- Fujii, M., H. Tsuchiya, T. Chujoh, T. Akizawa, and M. Seiki. 1992. Interaction of HTLV-I Tax1 with p67SRF causes the aberrant induction of cellular immediate early genes through CARG boxes. *Genes Dev.* **6**:2066-2076.

21. Fujii, M., H. Tsuchiya, and M. Seiki. 1991. HTLV-I Tax has distinct but overlapping domains for transcriptional activation and for enhancer specificity. *Oncogene* 6:2349-2352.
22. Fujisawa, J., M. Seiki, T. Kiyokawa, and M. Yoshida. 1985. Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor. *Proc. Natl. Acad. Sci. USA* 82:2277-2281.
23. Fujisawa, J., M. Seiki, M. Sato, and M. Yoshida. 1986. A transcriptional enhancer sequence of HTLV-I is responsible for trans-activation mediated by p40x of HTLV-I. *EMBO J.* 5:713-718.
24. Fujisawa, J., M. Toita, and M. Yoshida. 1989. A unique enhancer element for the *trans* activator (p40<sup>tax</sup>) of human T-cell leukemia virus type I that is distinct from cyclic AMP- and 12-*O*-tetradecanoylphorbol-13-acetate-responsive elements. *J. Virol.* 63:3234-3239.
25. Fujisawa, J., M. Toita, T. Yoshimura, and M. Yoshida. 1991. The indirect association of human T-cell leukemia virus Tax proteins with DNA results in transcriptional activation. *J. Virol.* 65:4525-4528.
26. Gessain, A., F. Barin, J. C. Vernant, O. Gout, L. Maurs, A. Calender, and G. De The. 1985. Antibodies to human T-lymphotropic virus type I in patients with tropical spastic paraparesis. *Lancet* ii:407-410.
27. Giam, C. Z., and Y. L. Xu. 1989. HTLV-I tax gene product activates transcription via pre-existing cellular factors and cAMP responsive element. *J. Biol. Chem.* 264:15236-15241.
28. Gonzalez, G. A., and M. R. Montminy. 1989. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. *Cell* 59:675-680.
29. Gonzalez, G. A., K. K. Yamamoto, W. H. Fischer, D. Karr, P. Menzel, W. Biggs III, W. W. Vale, and M. R. Montminy. 1989. A cluster of phosphorylation sites on the cyclic AMP-regulated nuclear factor CREB predicted by its sequence. *Nature (London)* 337:749-752.
30. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. *Mol. Cell. Biol.* 2:1044-1051.
31. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J. Gen. Virol.* 36:59-72.
32. Grassmann, R., C. Dengler, I. Muller-Fleckenstein, B. Fleckenstein, K. McGuire, M. Dokhalar, J. Sodroski, and W. Haseltine. 1989. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a herpesvirus saimiri vector. *Proc. Natl. Acad. Sci. USA* 86:3351-3355.
33. Hai, T. W., F. Liu, W. J. Coukos, and M. R. Green. 1989. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. *Genes Dev.* 3:2083-2090.
34. Hinuma, Y., H. Komoda, T. Chosa, T. Kondo, M. Kohakura, T. Takenaka, M. Kikuchi, M. Ichimaru, K. Yunoki, I. Sato, R. Matsuo, Y. Takiuchi, H. Uchino, and M. Hanaoka. 1982. Antibodies to adult T-cell leukemia virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nationwide sero epidemiologic study. *Int. J. Cancer* 29:631-635.
35. Hirai, H., J. Fujisawa, T. Suzuki, K. Ueda, M. Muramatsu, A. Tsuboi, N. Arai, and M. Yoshida. 1992. Transcriptional activator Tax of HTLV-1 binds to the NF- $\kappa$ B precursor p105. *Oncogene* 7:1737-1742.
36. Hirai, H., T. Suzuki, J.-I. Fujisawa, J.-I. Inoue, and M. Yoshida. 1994. Tax protein of human T-cell leukemia virus type I binds to the ankyrin motifs of inhibitory factor  $\kappa$ B and induces nuclear translocation of transcription factor NF- $\kappa$ B proteins for transcriptional activation. *Proc. Natl. Acad. Sci. USA* 91:3584-3588.
37. Hoeffler, J. P., T. E. Meyer, Y. Yun, J. L. Jameson, and J. F. Habener. 1988. Cyclic AMP-responsive DNA-binding protein: structure based on a cloned placental cDNA. *Science* 242:1430-1433.
38. Inoue, J., M. Seiki, T. Taniguchi, S. Tsuru, and M. Yoshida. 1986. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. *EMBO J.* 5:2883-2888.
39. Janknecht, R., G. deMartynoff, J. Lou, R. A. Hipskind, A. Nordheim, and H. G. Stunnenberg. 1991. Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. *Proc. Natl. Acad. Sci. USA* 88:8972-8976.
40. Jeang, K. T., I. Boros, J. Brady, M. Radonovich, and G. Khoury. 1988. Characterization of cellular factors that interact with the human T-cell leukemia virus type I p40<sup>x</sup>-responsive 21-base-pair sequence. *J. Virol.* 62:4499-4509.
41. Jeang, K. T., S. G. Widen, O. J. Semmes, and S. H. Wilson. 1990. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. *Science* 247:1082-1084.
42. Kliewer, S., C. Muchardt, R. Gaynor, and A. Dasgupta. 1990. Loss of a phosphorylated form of transcription factor CREB/ATF in poliovirus-infected cells. *J. Virol.* 64:4507-4515.
43. Leung, K., and G. J. Nabel. 1988. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. *Nature (London)* 333:776-778.
44. Lindholm, P. F., R. L. Reid, and J. N. Brady. 1992. Extracellular Tax1 protein stimulates tumor necrosis factor beta and immunoglobulin kappa light chain expression in lymphoid cells. *J. Virol.* 66:1294-1302.
45. Liu, F., and M. R. Green. 1990. A specific member of the ATF transcription factor family can mediate transcription activation by adenovirus E1A protein. *Cell* 61:1217-1224.
46. Maekawa, T., S. Matsuda, J. Fujisawa, M. Yoshida, and S. Ishii. 1991. Cyclic AMP response element-binding protein, CRE-BP1, mediates the E1A-induced but not the TAX-induced trans-activation. *Oncogene* 6:627-632.
47. Maekawa, T., H. Sakura, C. Kanei-Ishii, T. Sudo, T. Yoshimura, J. Fujisawa, M. Yoshida, and S. Ishii. 1989. Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain. *EMBO J.* 8:2023-2028.
48. Marriott, S. J., I. Boros, J. F. Duvall, and J. N. Brady. 1989. Indirect binding of human T-cell leukemia virus type I tax<sub>1</sub> to a responsive element in the viral long terminal repeat. *Mol. Cell. Biol.* 9:4152-4160.
49. Montagne, J., C. Beraud, I. Crenon, L. Platet, A. Gazzolo, A. Sergeant, and P. Jalinet. 1990. Tax1 induction of the HTLV-I 21 bp enhancer requires cooperation between two cellular DNA-binding protein. *EMBO J.* 9:957-964.
50. Montminy, M. R., and L. M. Bilezikjian. 1987. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. *Nature (London)* 328:175-178.
51. Montminy, M. R., K. A. Sevarino, J. A. Wagner, G. Mandel, and R. H. Goodman. 1986. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. *Proc. Natl. Acad. Sci. USA* 83:6682-6686.
52. Osame, M., K. Usuku, S. Izumo, N. Ijichi, H. Amitani, A. Igata, M. Matsumoto, and M. Tara. 1986. HTLV-I associated myelopathy, a new clinical entity. *Lancet* i:1031-1032.
53. Paca-Uccaralarkun, S., L. J. Zhao, N. Adya, J. V. Cross, B. R. Cullen, I. M. Boros, and C. Z. Giam. 1994. In vitro selection of DNA elements highly responsive to the human T-cell lymphotropic virus type I transcriptional activator, TAX. *Mol. Cell. Biol.* 14:456-462.
54. Paskalis, H., B. K. Felber, and G. N. Pavlakis. 1986. cis-acting sequences responsible for the transcriptional activation of a human T-cell leukemia virus type I constitute a conditional enhancer. *Proc. Natl. Acad. Sci. USA* 83:6558-6562.
55. Poiesz, B. J., R. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc. Natl. Acad. Sci. USA* 77:7415-7419.
56. Poteat, H. T., P. Kadison, K. McGuire, L. Park, R. E. Park, J. G. Sodroski, and W. A. Haseltine. 1989. Response of the human T-cell leukemia virus type I long terminal repeat to cyclic AMP. *J. Virol.* 63:1604-1611.
57. Sadowski, I., and M. Ptashne. 1989. A vector for expressing GAL4 (1-147) functions in mammalian cells. *Nucleic Acids Res.* 17:7539.
58. Seeler, J. S., C. Muchardt, M. Podar, and R. B. Gaynor. 1993. Regulatory elements involved in tax-mediated transactivation of the HTLV-I LTR. *Virology* 196:442-450.
59. Seeler, J.-S., C. Muchardt, A. Suessle, and R. B. Gaynor. 1994. Transcription factor PRDII-BF1 activates human immunodeficiency virus type 1 gene expression. *J. Virol.* 68:1002-1009.
60. Semmes, O. J., and K.-T. Jeang. 1992. Mutational analysis of human T-cell leukemia virus type I Tax: regions necessary for function determined with 47 mutant proteins. *J. Virol.* 66:7183-7192.
61. Shimotohno, K., M. Takano, T. Teruchi, and M. Miwa. 1986. Requirement of multiple copies of a 21-nucleotide sequence in the U3 region of human T-cell leukemia virus type I and type II long terminal repeats for trans-acting activation of transcription. *Proc. Natl. Acad. Sci. USA* 83:8112-8116.
62. Siekevitz, M., S. F. Josephs, M. Dukovich, N. Peffer, F. Wong-Staal, and W. C. Greene. 1987. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. *Science* 238:1575-1578.
63. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase. *Gene* 67:31-40.
64. Smith, M. R., and W. C. Greene. 1990. Identification of HTLV-I tax transactivator mutants exhibiting novel transcriptional phenotypes. *Genes Dev.* 4:1875-1885.
65. Smith, M. R., and W. C. Greene. 1992. Characterization of a novel nuclear localization signal in the HTLV-I tax transactivator protein. *Virology* 187:316-320.
66. Sodroski, J., C. Rosen, W. C. Goh, and W. Haseltine. 1985. A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus. *Science* 228:1430-1434.
67. Suzuki, T., J. I. Fujisawa, M. Toita, and M. Yoshida. 1993. The transactivator tax of human T-cell leukemia virus type 1 (HTLV-I) interacts with cAMP-responsive element (CRE) binding and CRE modulator proteins that bind to the 21-base-pair enhancer of HTLV-1. *Proc. Natl. Acad. Sci. USA* 90:610-614.
68. Suzuki, T., H. Hirai, J. Fujisawa, T. Fujita, and M. Yoshida. 1993. A transactivator Tax of human T-cell leukemia virus type 1 binds to NF-kappa B p50 and serum response factor (SRF) and associates with enhancer DNAs of the NF-kappa B site and CarG box. *Oncogene* 9:2391-2397.
69. Tan, T. H., M. Horikoshi, and R. G. Roeder. 1989. Purification and characterization of multiple nuclear factors that bind to the TAX-inducible en-

- hancer within the human T-cell leukemia virus type 1. *Mol. Cell. Biol.* **9**:1733–1745.
70. **Tanaka, A., C. Takahashi, S. Yamaoka, T. Nosaka, M. Maki, and M. Hatanaka.** 1990. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. *Proc. Natl. Acad. Sci. USA* **87**:1071–1075.
  71. **Taylor, A. K., I. Klisak, T. Mohandas, R. S. Sparkes, C. Li, R. Gaynor, and A. J. Lusis.** 1990. Assignment of the human gene for CREB1 to chromosome 2q32.3-q34. *Genomics* **7**:416–421.
  72. **Wagner, S., and M. R. Green.** 1993. HTLV-I tax protein stimulation of DNA binding of bZIP proteins by enhancing dimerization. *Science* **262**:395–399.
  73. **Watanabe, T., K. Yamaguchi, K. Takatsuki, M. Osame, and M. Yoshida.** 1990. Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be trans-activated by HTLV-1 tax gene. *J. Exp. Med.* **172**:759–765.
  74. **Yamamoto, K. K., G. A. Gonzalez, W. H. Biggs, and M. R. Montminy.** 1988. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. *Nature (London)* **334**:494–498.
  75. **Yoshimura, T., J. Fujisawa, and M. Yoshida.** 1990. Multiple cDNA clones encoding nuclear proteins that bind to the tax-dependent enhancer of HTLV-1: all contain a leucine zipper structure and basic amino acid domain. *EMBO J.* **9**:2537–2542.
  76. **Zhao, L., and C. Giam.** 1992. Human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21-base-pair repeats by protein-protein interaction. *Proc. Natl. Acad. Sci. USA* **89**:7070–7074.
  77. **Zhao, L. J., and C. Z. Giam.** 1991. Interaction of the human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator Tax with cellular factors that bind specifically to the 21-base-pair repeats in the HTLV-I enhancer. *Proc. Natl. Acad. Sci. USA* **88**:11445–11449.